News

Arshad Khanani, MD shares his excitement about the potential of elamipretide joining the treatment armamentarium in GA and his final thoughts on the topic.

Arshad Khanani, MD points to the viability of the mechanism of action of elamipretide for geographic atrophy in dry AMD, and what it could represent for patient outcomes.

Arshad Khanani, MD provides insight into the pivotal Phase 3 clinical trials investigating elamipretide for geographic atrophy in dry AMD.

Arshad Khanani, MD discusses the key findings on elamipretide from the Phase 2 ReCLAIM-2 clinical trial.

Arshad Khanani, MD describes the mechanism of action of elamipretide, an investigational product candidate for geographic atrophy in dry age-related macular degeneration.

Arshad Khanani, MD breaks down the current treatment options for geographic atrophy and provides insight into the therapeutic pipeline.

Mirum Pharmaceuticals submitted an NDA for chenodiol tablets to treat CTX based on positive phase 3 RESTORE trial results.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, discuss recent data assessing ruxolitinib cream for patients as young as 2 years old with atopic dermatitis.

Revisits and new antibiotic dispensations were rare, regardless of initial topical antibiotic treatment, in children with acute infectious conjunctivitis.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

Mannino, Anzueto and Christenson conclude the panel with thoughts on developing biologics for COPD, and increased interest in the field after ensifentrine and dupilumab.

Ahead of the anticipated FDA decision in September, an expert panel reviews the promising data and unique role dupilumab may have in COPD.

In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.

Davida Kruger, NP, joins the podcast to discuss updates in automated insulin delivery and continuous glucose monitoring systems from ADA 2024.

This analysis looked at children 1 to 11 years of age with eosinophilic esophagitis, highlighting the impacts of dupilumab on EoE.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

Nearly half of patients with CKD presented with iron deficiency at the initial presentation at the nephrology department.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.

Aquestive Therapeutics announced positive topline data from the trial on June 25, 2024.

Inconsistent estimates of self-reported impairment across surveys could impact surveillance on the size of the population with vision problems.

Following this post-hoc analysis, additional research may be necessary to assess other safety implications of a dose increase of abrocitinib for atopic dermatitis patients prior to Week 12.

These data pointed to a low risk of persistent IOP increases of intravitreous 0.1-mL injection volumes administered for 1 year in eyes with GA.

These data suggest that quality of life, assessed by DLQI, may be implemented in determining treatment efficacy among patients with psoriasis.

The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.